RB1CC1 Inhibitors

RB1CC1 inhibitors as a chemical class largely consist of compounds that modulate the autophagy pathway. This modulation occurs either through the inhibition of enzymatic activity that is upstream of autophagy induction or through interference with the autophagosomal machinery itself. By targeting the molecular components that regulate autophagy, these inhibitors indirectly influence the function of RB1CC1, which is a facilitator of autophagy. The compounds listed do not inhibit RB1CC1 directly but impact the biological processes it is associated with. Compounds like 3-Methyladenine, Wortmannin, and LY294002 inhibit the class III PI3Ks, thereby preventing the initiation of autophagy.

Moreover, compounds that affect the fusion of autophagosomes with lysosomes, such as Chloroquine and Hydroxychloroquine, or those that interfere with lysosomal acidification, like Bafilomycin A1, alter the autophagic flux, thereby influencing RB1CC1 activity. In the context of RB1CC1 involvement in autophagy, the autophagy-initiating ULK1 kinase complex and mTOR, a major negative regulator of autophagy, are also critical targets. SBI-0206965 and MHY1485 modulate these kinases, impacting the cellular processes RB1CC1 is a part of. Additionally, chemical inhibitors like U0126, while primarily known for their effects on the MAPK/ERK pathway, may also exert influence on autophagic pathways. Through these varied modes of action, each chemical listed contributes to the modulation of RB1CC1 activity within the cell.